Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade

Circulation

Volumn 97, Issue 17, 1998, Pages 1680-1688

  Mascelli, Mary A ^a,b   Lance, Ellen T ^a   Damaraju, Lakshmi ^a   Wagner, Carrie L ^a   Weisman, Harlan F ^a   Jordan, Robert E ^a  

^a CENTOCOR INC   (United States)

^b Clinical Pharmacology   (United States)

Author keywords

Drugs; Pharmacology; Receptors

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HISTOGRAM; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; MALE; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RADIOMETRY; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE LIFESPAN; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0032485876     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.17.1680     Document Type: Article

References (33)

1. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
2. The EPIC Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
3. Coller BS. A new murine monoclonal antibody reports an activation- dependent change in the conformation and/or micro environment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest. 1985;76:101-107.
4. 3 integrin receptors: a potential mechanism for the prevention of restenosis. J Am Coll Cardiol. 1997;29:243A. Abstract.
5. Larson RS, Springer TA. Structure and function of leukocyte integrins. Immunol Rev. 1990;114:181-217.
6. Reverter JC. Béguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J Clin Invest. 1996;98:863-874.
7. Coller BS, Peerschke EI, Seligsohn U, Scudder LE, Nurden AT, Rosa JP. Studies on the binding of an alloimmune and two murine monoclonal antibodies to the platelet glycoprotein IIb/IIIa complex receptor. J Lab Clin Med. 1986;107:384-392.
8. Coller BS. Activation affects access to the platelet receptor for adhesive glycoproteins. J Cell Biol. 1986;103:451-456.
9. Cohen I, Burk DL, White JG. The effect of peptides and monoclonal antibodies that bind to platelet glycoprotein IIb-IIIa complex on the development of clot tension. Blood. 1989;73:1880-1887.
10. Ware JA, DeCenzo MT, Smith M, Saitoh M. Calcium mobilization and glycoprotein IIb-IIIa complex ligands in epinephrine-stimulated platelets. Am J Physiol. 1991;91:H1619-H1624.
11. Ware JA, Rang J, DeCenzo MT, Smith M, Watkins SC, Slayter HS, Saitoh M. Platelet activation by a synthetic Hydrophobic polymer, polymethacrylate. Blood. 1991;78:1713-1721.
12. Cox A, Devine DV. Factor XIII binding to activated platelets is mediated through activation of glycoprotein IIb-IIIa. Blood. 1994;83:1006-1016.
13. Coller B, Folts JD, Smith SR, Scudder LE, Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GP IIb/IIIa receptor. Circulation. 1989;80:1766-1774.
14. Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT. Guerrero JL. Leinbach RC, Ziskind AA, Collen D. Rapid and sustained coronary recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation. Circulation. 1988;77:670-677.
15. Harrison P, Wilbourn B, Cramer E, Faint R, Mackie IJ. Bhattacharya S, Lahiri A, Tenza D, Machin SJ, Savidge GF. The influence of therapeutic blocking of GP IIb/IIIa on platelet α-granular fibrinogen. Br J Haematol. 1992;82:721-728.
16. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin anti-platelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 1994;90:1757-1764.
17. Konstantopoulos K, Kamat SG, Schafer AI, Bañez EI, Jordan R, Kleiman NS, Hellums JD. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Circulation. 1995;91: 1427-1431.
18. Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor- activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GP IIb/IIIa receptors. J Am Coll Cardiol. 1995;26:1665-1671.
19. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1969;194:927-929.
20. Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GP IIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood. 1996;88:907-914.
21. Mascelli MA, Worley S, Veriabo NJ, Lance ET, Mack S, Schaible T, Weisman HF, Jordan RE. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy. Circulation. 1997;96:3860-3866.
22. Jordan RE, Wagner CA, Mascelli MA, Treacy G, Nedelman MA, Woody JN, Weisman HF, Coller BS. Preclinical development of c7E3 Fab: a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GP IIb/IIIa. In: Horton MA, ed. Adhesion Receptors as Therapeutic Targets. Boca Raton, Fla: CRC Press; 1996:327-355.
23. Coller BS, Scudder LE, Beer J, Gold HK, Foils JD, Cavagnaro J, Jordan R, Wagner C, Iuliucci J, Knight D, Ghrayeb J, Smith C, Weisman HF, Berger H. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann N Y Acad Sci. 1991;614:193-213.
24. Eika C. The platelet aggregating effect of eight commercial heparins. Scand J Haematol. 1972;9:480-482.
25. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest. 1980;65:64-73.
26. Thomson C, Forbes CD, Prentice CRM. The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. Clin Sci Mol Med. 1973;45:484-494.
27. Steele PM, Chesebro JH, Stanson AW, Holmes DR, Dewanjee MK, Badimon L, Fuster V. Balloon angioplasty: natural history of pathophysical response to injury in a pig model. Circ Res. 1985;57:105-112.
28. Chrisopoulos C, Mackie I, Lahiri A, Machin S. Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to glycoprotein IIb-IIIa. Blood Coagul Fibrinolysis. 1993;4:729-737.
29. Coller BS, Seligsohn U, Zivelin E, Zwang A, Lusky A, Modan M. Immunologic and biochemical characterization of homozygous and heterozygous Glanzmann's thrombasthenia in Iraqi-Jewish and Arab populations of Israel: comparisons of techniques for carrier detection. Br J Haematol. 1986;62:723-735.
30. 111indium-labeled human platelets. Br J Haematol. 1980;44:269-280.
31. Wagner CL, Cunningham MR, Wyand MS, Weisman HF, Coller BS, Jordan RE. Reversal of the anti-platelet effects of chimeric 7E3 Fab treatment by platelet transfusion in cynomolgus monkeys. Thromb Haemost. 1995;73:1313. Abstract.
32. Boehrer JD, Kereiakes DJ, Navella FI, Califf RM, Topol EJ. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. Am J Cardiol. 1994;74:1166-1170.
33. Knight DM, Wagner C, Jordan R, McAleer MF, DeRita R, Fass DN, Coller BS, Weisman HF, Ghrayeb J. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Imuno. 1995;32:1271-1281.